Full-Time
Confirmed live in the last 24 hours
Develops precision medicines for rare diseases
No salary listed
Senior
Remote in Germany
Candidate must live within the identified territory within country level.
SpringWorks Therapeutics develops and commercializes precision medicines aimed at treating rare diseases and cancer. Their approach focuses on tailoring treatments to the genetic and molecular characteristics of diseases, which helps enhance the effectiveness and safety of their therapies for patients who often have limited options. The company operates within the biopharmaceutical sector, acquiring and developing innovative therapies, and collaborates with other pharmaceutical firms to bring these treatments to market. SpringWorks targets a specific group of patients with unique genetic profiles, providing them with potentially life-changing therapies that are not commonly available. They are actively conducting clinical trials, including Phase 1b and 2 studies, to assess the safety and effectiveness of their drug candidates.
Company Size
201-500
Company Stage
IPO
Headquarters
New York City, New York
Founded
2017
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Paid Vacation
Paid Sick Leave
Professional Development Budget
Flexible Work Hours
Remote Work Options
Merck KGaA, Darmstadt, Germany, and SpringWorks Therapeutics, have entered into a definitive agreement for us to acquire SpringWorks.
When SpringWorks went public in 2019, the biotech priced its shares at $18 each.
German Merck Group has announced a $3.9 billion acquisition agreement with U.S. biopharmaceutical company SpringWorks Therapeutics. This acquisition aims to enhance Merck's cancer drug business. SpringWorks Therapeutics, a biopharmaceutical developer, has obtained four potential new drugs in clinical stages from Pfizer.
Merck announced it will acquire SpringWorks Therapeutics for approximately $3.9 billion, with a purchase offer of $47 per share, which is 26% above the average price before February 2025 market speculations. The acquisition aims to expand Merck's sales in the cancer treatment sector. The deal involves a cash payment to SpringWorks Therapeutics, based in Connecticut, USA.
Merck KGaA, a German healthcare and materials group, announced an agreement to acquire U.S. biotechnology company SpringWorks Therapeutics for an equity value of $3.9 billion. The acquisition aims to strengthen Merck's cancer drug business. The cash purchase price is $47 per share, representing an enterprise value of $3.4 billion (€3 billion) after deducting SpringWorks' cash holdings. The companies recently concluded negotiations on the $47 per share offer.